Immix Biopharma Inc (IMMX)

May 01, 2025

Immix Biopharma (IMMX) to Release Earnings on Thursday - Defense World

May 01, 2025

Apr 30, 2025

Favourable Signals For Immix Biopharma: Numerous Insiders Acquired Stock - simplywall.st

Apr 30, 2025

Apr 23, 2025

Immix Biopharma Announces Oral Presentation of NXC-201 Phase 1/2 Trial Data at ASCO 2025 - Nasdaq

Apr 23, 2025

Apr 23, 2025

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025 - GlobeNewswire

Apr 23, 2025

Apr 23, 2025

Groundbreaking CAR-T Therapy for AL Amyloidosis: First US Trial Data Earns Prestigious ASCO Spotlight - Stock Titan

Apr 23, 2025

Mar 28, 2025

Immix Biopharma (IMMX) Expected to Announce Earnings on Friday - Defense World

Mar 28, 2025

Mar 27, 2025

Immix Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 25, 2025

Immix Biopharma Inc. (IMMX) reports earnings - Quartz

Mar 25, 2025

Mar 20, 2025

Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 20, 2025

Mar 13, 2025

Immix Biopharma — NXC-201 receives FDA RMAT designation - Smartkarma

Mar 13, 2025

Mar 12, 2025

SBI Securities Co. Ltd. Purchases New Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Mar 12, 2025

Mar 04, 2025

Immix Biopharma (NASDAQ:IMMX) Trading Down 9% – Here’s Why - Defense World

Mar 04, 2025

Feb 13, 2025

HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat

Feb 13, 2025

Feb 12, 2025

Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright - MSN

Feb 12, 2025

Feb 11, 2025

Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com South Africa

Feb 11, 2025

Feb 11, 2025

Immix Biopharma’s (IMMX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Feb 11, 2025

Feb 10, 2025

Immix Biopharma’s CAR-T NXC-201 Snags FDA RMAT Designation for Light Chain Amyloidosis - CGTLive™

Feb 10, 2025

Feb 10, 2025

Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201 - TipRanks

Feb 10, 2025

Feb 10, 2025

Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy - Marketscreener.com

Feb 10, 2025

Feb 10, 2025

Immix Biopharma Receives FDA RMAT Designation For NXC-201 -February 10, 2025 at 10:15 am EST - Marketscreener.com

Feb 10, 2025

Feb 10, 2025

Think Lucid Group is Expensive? This Chart Might Change Your Mind. - The Globe and Mail

Feb 10, 2025

Feb 10, 2025

Immix Biopharma Receives FDA Regenerative Medicine Advanced - GlobeNewswire

Feb 10, 2025

Feb 10, 2025

Breakthrough: IMMX Secures Elite FDA Status for First-Ever AL Amyloidosis CAR-T Treatment - StockTitan

Feb 10, 2025

Feb 06, 2025

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - The Globe and Mail

Feb 06, 2025

Feb 06, 2025

Immix Biopharma : Presentation (IMMX Corporate presentation February 2025) - Marketscreener.com

Feb 06, 2025

Feb 06, 2025

Is Qualcomm Stock a Buy Even Without Huawei Deal? - The Globe and Mail

Feb 06, 2025

Feb 05, 2025

Several Insiders Invested In Immix Biopharma Flagging Positive News - Yahoo Finance

Feb 05, 2025

Jan 20, 2025

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 11.0% in December - MarketBeat

Jan 20, 2025

Jan 14, 2025

Geode Capital Management LLC Has $224,000 Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Jan 14, 2025

Jan 10, 2025

FY2024 EPS Estimate for Immix Biopharma Lowered by Analyst - Defense World

Jan 10, 2025

Jan 09, 2025

HC Wainwright Predicts Weaker Earnings for Immix Biopharma - MarketBeat

Jan 09, 2025

Jan 09, 2025

Immix Biopharma Inc (IMMX-Q) QuotePress Release - The Globe and Mail

Jan 09, 2025

Jan 08, 2025

Immix Biopharma, Inc. Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T - Marketscreener.com

Jan 08, 2025

Jan 08, 2025

HC Wainwright Reaffirms “Buy” Rating for Immix Biopharma (NASDAQ:IMMX) - Defense World

Jan 08, 2025

Jan 07, 2025

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T - The Manila Times

Jan 07, 2025

Jan 07, 2025

Immix Biopharma Completes Critical Phase 1b Safety Trial for Novel AL Amyloidosis CAR-T Therapy - StockTitan

Jan 07, 2025

Jan 06, 2025

Analyst maintains Buy on Immix Biopharma on initial results of NEXICART-2 trial - Investing.com India

Jan 06, 2025

Jan 06, 2025

Analyst maintains Buy on Immix Biopharma on initial results of NEXICART-2 trial By Investing.com - Investing.com South Africa

Jan 06, 2025

Jan 06, 2025

Immix Biopharma (NASDAQ:IMMX) Given "Buy" Rating at HC Wainwright - MarketBeat

Jan 06, 2025

Dec 26, 2024

Immix Biopharma director Jason Hsu acquires shares worth $104,358 By Investing.com - Investing.com Canada

Dec 26, 2024

Dec 20, 2024

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis - BioSpace

Dec 20, 2024

Dec 19, 2024

Immix Biopharma reports early success in CAR-T trial - Investing.com

Dec 19, 2024

Dec 19, 2024

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 - The Bakersfield Californian

Dec 19, 2024

Dec 19, 2024

Immix Biopharma (IMMX) Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis - StreetInsider.com

Dec 19, 2024

Dec 16, 2024

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 17.5% in November - MarketBeat

Dec 16, 2024

Dec 16, 2024

Immix Biopharma reports promising CAR-T therapy results - Investing.com

Dec 16, 2024

Dec 16, 2024

Terex Corp (TEX-N) QuotePress Release - The Globe and Mail

Dec 16, 2024